Your browser doesn't support javascript.
loading
Cost-effectiveness of school-based asthma screening in an urban setting.
Gerald, Joe K; Grad, Roni; Bailey, William C; Gerald, Lynn B.
Afiliación
  • Gerald JK; Division of Community, Environment and Policy, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Ariz 85724, USA. geraldj@email.arizona.edu
J Allergy Clin Immunol ; 125(3): 643-50, 650.e1-650.e12, 2010 Mar.
Article en En | MEDLINE | ID: mdl-20226298
BACKGROUND: Much has been done to promote population-based childhood asthma screening; however, concerns remain regarding its cost-effectiveness. OBJECTIVES: To conduct a cost-effectiveness analysis of school-based asthma screening strategies. METHODS: A 5 health state Markov approach (symptom-free, symptom, exacerbation recovery, emergency department, and hospitalization day) was used to evaluate school-based screening in a simulated population of urban elementary-age school children. Two questionnaire and 2 multistage strategies incorporating spirometry or spirometry with exercise testing were evaluated from the societal perspective by using 365 daily cycles. The outcome was 2006 dollars per quality-adjusted life year (QALY). RESULTS: The most efficient strategy identified children with previously diagnosed but poorly controlled asthma at a cost of $150,000 per QALY (95% CI, $65,800-$318,000). Uncertainty surrounding the cost-effectiveness estimate was primarily a result of the symptom day preference weight estimate (44%), the probability of confirmation after screening (17%), the adequacy of asthma control in the population (9%), and the estimated treatment effect on symptoms (6%). Screening generated an additional 21 symptom-free day equivalents per child identified with previously diagnosed but not well controlled asthma and led to $85.55, $12.36, and $2.58 in additional screening, daily treatment, and indirect costs and $5.01 less in emergency department and hospitalization costs. CONCLUSION: Population-based asthma screening is not cost-effective at $50,000 per QALY and has only a 20% chance of being cost-effective at $100,000 per QALY. The most efficient approach is to screen for previously diagnosed but poorly controlled asthma. Linking screening with better treatment, and long-term adherence strategies might yield future cost-effective approaches.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Tamizaje Masivo Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Aspecto: Patient_preference Límite: Adolescent / Child / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2010 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Tamizaje Masivo Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Aspecto: Patient_preference Límite: Adolescent / Child / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2010 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos